A PHASE 1, OPEN-LABEL, RANDOMIZED, FIXED-SEQUENCE, PARALLEL-COHORT STUDY TO ESTIMATE THE EFFECT OF FLUVOXAMINE OR FLUCONAZOLE, ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF A SINGLE DOSE OF PF-04965842 IN HEALTHY SUBJECTS
Phase of Trial: Phase I
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Abrocitinib (Primary) ; Fluconazole; Fluvoxamine
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 02 Jan 2019 Status changed from recruiting to completed.
- 18 Oct 2018 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.
- 18 Oct 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2018.